FDFT1

Squalene synthase · P37268 · FDFT1 on Sugi Atlas →

14,242 patent compounds predicted against FDFT1, 7,596 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Potassium Ion (SCHEMBL415176)	1.00	19/20
Potassium Ion (SCHEMBL417191)	1.00	19/20
Potassium Ion (SCHEMBL418708)	1.00	19/20
SCHEMBL418707	0.71	19/20
Potassium (SCHEMBL418709)	0.71	19/20
Potassium Ion (SCHEMBL884046)	0.68	19/20
SCHEMBL416625	0.68	19/20
Potassium (SCHEMBL416627)	0.68	19/20
Potassium Ion (SCHEMBL884055)	0.68	19/20
Potassium Ion (SCHEMBL884120)	0.68	19/20
SCHEMBL412549	0.67	19/20
Potassium (SCHEMBL412551)	0.67	19/20
SCHEMBL413443	0.67	19/20
Potassium (SCHEMBL413445)	0.67	19/20
SCHEMBL417190	0.67	19/20
Potassium (SCHEMBL417192)	0.67	19/20
SCHEMBL1235605	0.67	19/20
Potassium Ion (SCHEMBL2066199)	0.67	19/20
SCHEMBL415641	0.67	19/20
Potassium (SCHEMBL415643)	0.67	19/20

Clinical trials — most relevant to FDFT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia	PHASE3	COMPLETED
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia	PHASE3	COMPLETED
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.	PHASE3	COMPLETED
Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia	PHASE2	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate	PHASE2	WITHDRAWN
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults	PHASE2	UNKNOWN
Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis	PHASE2	COMPLETED
Hereditary Sensory Neuropathy Serine Trial	PHASE2	UNKNOWN
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease	EARLY_PHASE1	COMPLETED
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
Familial Partial Lipodystrophy Study	nan	COMPLETED
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism	nan	COMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN)	nan	COMPLETED
De Novo Lipogenesis in Severity of NAFLD	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism	nan	COMPLETED
Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings	nan	NOT_YET_RECRUITING
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Genetic Study of Sitosterolemia	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects	nan	UNKNOWN
11C-Acetate PET/CT Non-FDG-Avid Tumors	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a FDFT1 binder may also engage these)

Protein	Name	Similarity
Q5R6U3	—	1.000	Q5R6U3 →
P53798	—	1.000	P53798 →
Q32KR6	—	1.000	Q32KR6 →
A0A1P7Y0D0	—	1.000	A0A1P7Y0D0 →
Q02769	—	1.000	Q02769 →
O74165	—	1.000	O74165 →
P53800	—	1.000	P53800 →
A0A345BJQ0	—	1.000	A0A345BJQ0 →
D0VFU8	—	1.000	D0VFU8 →
A0A3G1DJL2	—	0.998	A0A3G1DJL2 →
Q9HGZ6	—	0.997	Q9HGZ6 →
P29704	—	0.997	P29704 →
P53799	—	0.997	P53799 →
C9E894	—	0.996	C9E894 →
O48666	—	0.995	O48666 →
A0A1P7Y0C9	—	0.994	A0A1P7Y0C9 →
A0A1D8PI71	—	0.994	A0A1D8PI71 →
P78589	—	0.994	P78589 →
Q54DR1	—	0.993	Q54DR1 →
P36596	—	0.992	P36596 →
V6RPN0	—	0.992	V6RPN0 →
D2K762	—	0.991	D2K762 →
A0A1P7Y0A8	—	0.990	A0A1P7Y0A8 →
A0A1P7Y0A2	—	0.989	A0A1P7Y0A2 →
Q92459	—	0.989	Q92459 →
Q752X9	—	0.989	Q752X9 →
A0A1P7Y0D4	—	0.989	A0A1P7Y0D4 →
Q7S4Z6	—	0.989	Q7S4Z6 →
O65688	—	0.988	O65688 →
Q4WAG4	—	0.987	Q4WAG4 →